Global Blood's novel sickle cell drug approved
The FDA yesterday approved a new, once-daily drug to treat sickle cell disease that has a unique mechanism: It boosts hemoglobin, and by extension oxygen transport, in the bloodstream. The drug, called Oxbryta, was developed by Global Blood Therapeutics — and achieved approval three months earlier than projected.
It will cost $125,000 per year before discounts.
For a long time, there were few options for patients with sickle cell disease. That’s changing: Several gene therapies are in the works, and the FDA approved a monoclonal antibody drug from Novartis called crizanlizumab, or Adakveo, just a couple days ago.
It will cost $125,000 per year before discounts.
For a long time, there were few options for patients with sickle cell disease. That’s changing: Several gene therapies are in the works, and the FDA approved a monoclonal antibody drug from Novartis called crizanlizumab, or Adakveo, just a couple days ago.
No hay comentarios:
Publicar un comentario